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OBJECTIVE: The aim of this study was to determine
concurrence of administrative claims data and medical
records abstraction data with regard to selected comor-
bid conditions among hypertensive subjects.
METHODS: Study subjects were incident hypertensives
identified by: 1) at least one claim with an ICD-9 diagno-
sis code of hypertension and at least one claim for an
anti-hypertensive drug; or 2) at least two claims with an
ICD-9 diagnosis code of hypertension, preceded by at
least 6 months of health plan enrollment free of anti-
hypertensive prescriptions. Nurse abstractors reviewed
medical records for documentation of seven comorbid
conditions, including ischemic heart disease, congestive
heart failure, chronic renal failure, cerebrovascular dis-
ease, complicated hypertension, hyperlipidemia, and dia-
betes. To determine whether comorbidities noted in med-
ical records data appeared in claims data, we reviewed
physician, facility, and pharmacy claims for a 12-month
period after the initial hypertension indicator to identify
ICD-9 diagnosis codes, CPT procedure codes, or pre-
scriptions for drugs of interest.
RESULTS: 118 subjects were included in the analysis.
Claims and medical records data, respectively, identified
ischemic heart disease (14 of 15); congestive heart failure
(7 of 10); chronic renal failure (0 of 1); cerebrovascular
disease (3 of 1); complicated hypertension (18 of 3); hy-
perlipidemia (44 of 73); and diabetes (25 of 18).
CONCLUSION: The extent to which claims data identi-
fied comorbidities compared to medical records data var-
ied greatly by comorbid condition. Some of this variation
may be due to limitations of medical records and claims
data, including: 1) subjects may have seen additional phy-
sicians whose records were not abstracted, but subjects’
comorbidities were in claims data; 2) medical records may
not contain a patient’s diagnosis, but pharmacy claims
contain therapies; and 3) claims data may not identify
chronic conditions if a patient is not receiving therapy.
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Confounding by indication may account for the observed
elevated risk of acute myocardial infarction in hyperten-
sives treated with calcium antagonists (CA). If CAs are
preferentially prescribed for sicker patients, then in-
creased risk of adverse events is due partly to the underly-
ing disease, not the medication.
OBJECTIVE: To test the hypothesis that confounding by
indication occurs.
METHODS: Pennsylvania Medicaid claims data were
used to conduct a retrospective cohort analysis of hyper-
tensive enrollees who received anti-hypertensive mono-
therapy. Diagnoses of 12 known cardiovascular risk fac-
tors recorded on medical claims 7 days or less prior to
the start of anti-hypertensive drug therapy were exam-
ined. Logistic regression analysis was performed to evalu-
ate the association between each prior diagnosis and sub-
sequent CA use, controlling for demographic variables
and other relevant diagnoses. Since CA use was not rare,
we approximated the risk ratio (RR) from the adjusted
odd ratio using the formula: RR  OR/(1  P)  (P 
OR) where P is the non-exposed group.
RESULTS: CAs were prescribed significantly more often
than other monotherapy for patients with prior diag-
noses of: arteriosclerotic cardiovascular disease (RR 
3.06; 95% CI 1.96–3.82); angina (RR  2.03; 95% CI
1.51–2.58); COPD (RR  1.76; 95% CI 1.14–2.45); dia-
betes (RR  1.34; 95% CI 1.06–1.66); and ischemic
heart disease (RR  1.61; 95% CI 1.07–2.25).
CONCLUSION: There is strong evidence that confound-
ing by indication occurred in this population. Findings of
adverse outcomes based on observational studies of CA
therapy may arise from unrecognized confounding. This
possibility should be considered in the design of observa-
tional pharmacotherapy outcomes studies.
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Guidelines for the evaluation and management of heart
failure recommend different drug therapies for congestive
heart failure (CHF) patients with left-ventricular (LV)
systolic dysfunction versus those with normal LV systolic
function (LVERSUSF). To what extent these guidelines
are translated into differing prescribing in actual practice
is unknown.
OBJECTIVE: To compare drug utilization in hospitalized
CHF patients with and without LV systolic dysfunction.
METHODS: Medical records were reviewed for all patients
with a principal discharge diagnosis of CHF from January 1
through June 30, 1997 at an urban public hospital (N 
387). LVERSUSF assessments performed within 6 months
before discharge were used to classify LVERSUSF. Pre-
scribed drug therapies were determined at discharge.
RESULTS: Of 207 patients with LV systolic dysfunction,
161 (81.0%) patients were discharged on an angiotensin-
converting enzyme (ACE) inhibitor, versus 66 (71.0%) of
93 patients with normal LVERSUSF (p  0.05). After ex-
cluding patients with contraindications of ACE inhibitor
use, the difference in ACE inhibitor use between the pa-
tients with and without LV systolic dysfunction was not
significant (p  0.09). No statistically significant differ-
ences were observed between patients with and without
LV systolic dysfunction regarding the utilization of di-
uretics (90.0% versus 91.0%), beta blockers (3.0% ver-
sus 4.0%), and alpha blockers (4.0% versus 6.0%).
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CONCLUSIONS: Regardless of LVERSUSF, prescribed
drug therapies at discharge were similar among patients
hospitalized for CHF in the hospital. Findings indicate a
need to better understand the role and actual implemen-
tation of guidelines that recommend customized CHF
drug therapy tailored to LVERSUSF.
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OBJECTIVES: The GOALS (Gauging Overall Attain-
ment of Lipid Standards) study, a retrospective chart re-
view of 1727 geographically diverse US adult patients
with hyperlipidemia, examined the extent to which pa-
tients met National Cholesterol Education Program
(NCEP) guidelines after treatment with various HMG-
CoA reductase inhibitors (“statins”).
METHODS: For this study 1500 physicians (family prac-
titioners and cardiologists) were randomly selected from
national lists. Forty-five physicians (37 FPs, 8 cardiolo-
gists) provided data on at least 40 hyperlipidemic pa-
tients. Each physician was asked to abstract data from
the medical charts of at least 10 atorvastatin patients, 10
simvastatin patients, and 20 patients who received any
statin between January 1996 and June 1998.
RESULTS: Patients were aged 20–96, 52% female, and
87% white. The most common primary prevention risk
factors were age (73%) and hypertension (58.8%). There
were no statistically significant differences in gender,
race, age at diagnosis, or source of reimbursement be-
tween patients using atorvastatin (n  195), simvastatin
(n  389), pravastatin (n  156), other statins (n  206),
or patients using various statins serially over the time pe-
riod (n  781). Similarly, there were no statistically sig-
nificant differences between the patients in these groups
in terms of secondary prevention risk factors (previous
myocardial infarction [MI], coronary artery disease
[CAD], peripheral vascular disease [PVD], or coronary
vascular disease [CVD]). Patients treated with atorva-
statin alone were significantly more likely to reach the
NCEP LDL-C treatment goal in a shorter time span (log-
rank test chi-square 52.20, p  0.0001).
CONCLUSIONS: This retrospective analysis reinforces
recent randomized trials suggesting hyperlipidemic pa-
tients using atorvastatin may be more likely to reach
NCEP LDL-C treatment goals faster than those using
other statins. Further analysis of patients using combina-
tion therapy is required.
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OBJECTIVE: The purpose of this study was to develop a
method of value analysis which would facilitate an objec-
tive comparison of available angiotensin II antagonists as
blood pressure lowering agents, in order to provide an
adaptable framework to allow for future clinical develop-
ments and new product introduction.
METHODS: The four angiotensin II antagonists avail-
able for analysis were candesartan, irbesartan, losartan,
and valsartan. The analysis was conducted under the aus-
pices of a team comprised of a cardiologist, a physician
and a pharmacist; the pharmacist was responsible for co-
ordination of the process. A nine-point selection criteria
set was developed and each criterion assigned a relative
weight value by the team. Each drug product was system-
atically evaluated against each criterion to generate a se-
ries of product-criterion scores. A total score for each
product was derived from the sum of product-criterion
score multiplied by the respective criterion weighted
value determined previously. The results were analyzed
and the model tested for sensitivity to parameter changes
where any doubts existed concerning the scoring process.
Results and outcomes were presented to the Drug and
Therapeutics Committee.
RESULTS: The initial analysis generated scores which
were similar for irbesartan (831) and candesartan (822).
These scores appeared to be significantly higher than
those obtained for valsartan (764) and losartan (706).
Following consideration of the impact of sensitivity tests
in the model, it had been previously decided that changes
in parameters reflecting efficacy were warranted and so
revised scores for candesartan (901) and irbesartan (871)
were calculated.
CONCLUSIONS: The results were presented to the Drug
and Therapeutics Committee and consequently the addi-
tion of candesartan and removal of losartan from the for-
mulary were formally approved.
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OBJECTIVE: The study purpose was to evaluate the
utility of a patient and prescriber program to increase the
use of antilipemics and/or estrogen in at-risk members
for CAD.
METHODS: Prescription claims from two employer
groups were screened to identify surrogate risk factors
for the development of CAD based on: nitrates, diabetic
claims, tobacco cessation products, and postmenopausal
women not receiving estrogen or cholesterol-lowering
